Medicon Valley Biomedical Newsletter

The capital base of Astion Pharma A/S was recently increased by EUR 6,7 million to strengthen the company's development activities in the field of medical treatment of skin diseases. The fresh cap...

Curalogic A/S has entered the Copenhagen Stock Exchange. The total number of shares in Curalogic were 4,553,602 shares including 375,000 shares as the over allotment option was exercised in full. The ...

DuoCort AB, a privately-held Swedish drug development company, has reported that the European Commission has granted an Orphan Medicinal Product Designation to its new hydrocortisone dual-release oral...

Fisher Biosciences has acquired BioImage A/S to expand its offering in high content screening and analysis reagent technologies. BioImage complements Fisher Biosciences' existing Cellomics busines...

Gastrotech Pharma A/S has announced the initiation a new clinical Phase II study of GTP-200 in cancer cachexia patients. The study is designed as a double blind, randomized, controlled study in 30 pat...

H. Lundbeck A/S and Forest Laboratories, Inc. have announced that the U.S. District Court for the District of Delaware has determined that the U.S. patent covering escitalopram, the active ingredient ...

Lundbeck A/S has decided to investigate Lu AA21004 for the treatment of depression in patients and will enrol the first patient in a 400 patient phase II study by the end of third quarter 2006. The de...

Medicon A/S opens its second office in Sweden. In addition to its Malmö office, from June 2006. Medicon will also run an office in Kista, ideally located between Stockholm City and Arlanda Airport wit...

Novo Nordisk A/S has announced that the European Commission has approved the rapid-acting insulin NovoRapid for use by pregnant women with diabetes. The approval follows results of the largest ever ra...

Novo Nordisk A/S and Aradigm Corporation have announced an agreement whereby Novo Nordisk acquires certain patent rights from Aradigm Corporation as part of a restructuring of the existing licence agr...

Novozymes A/S expects to sign a research agreement with China Resources Alcohol Corporation, CRAC, on the development of biomass for biofuel in China. From August, Novozymes and China Resources...

Nycomed A/S has announced the acquisition of Romanian pharmaceutical company, Ruby De Tacos, thereby further strengthening its European presence. Ruby De Tacos has 30 employees and already mark...

EMEA, the European Medicines Agency has announced that it has recommended the European Commission to grant orphan drug designation to Pharmexa A/S for its peptide vaccine GV1001 for the treatment of p...

Santaris Pharma A/S and Enzon Pharmaceuticals Inc. have entered into a collaboration to co-develop and commercialize a series of innovative RNA Antagonists based on Santaris Pharma's locked nucleic ac...

Synarc Inc. and the Center for Clinical and Basic Research A/S, CCBR, a Denmark-based corporation with expertise in implementing clinical research studies, have announced that they have reached an agr...

The EU Commission has granted TopoTarget A/S marketing approval for the company's first product, Savene, a drug protecting a patient's tissue from accidental exposure to anthracyclines adminis...

TopoTarget A/S and CuraGen Corp. have announced the initiation of patient dosing in a Phase I clinical trial evaluating the safety and tolerability of PXD101, a small molecule histone deacetylase, HDA...

TopoTarget A/S and CuraGen have announced the initiation of patient dosing in a phase I/II clinical trial evaluating the safety and potential efficacy of PXD101, a small molecule histone deacetylase, ...